Research Progress on Parthenolide in the Treatment of Leukemia
Objective To provide a reference for the treatment of leukemia with parthenolide(PTL).Methods The relevant literature from 2000 to 2023 was searched from the CNKI,WanFang,VIP,and PubMed to analyze the pharmacological activity and mechanism of PTL in the treatment of leukemia,the clinical application and dosage form improvement methods of PTL were summarized.Results For acute leukemia,PTL can promote the apoptosis of acute leukemia cells and affect the cell cycle by inhibiting the nuclear factor κ-light-chain-enhancer of activated B cells(NF-κB),affecting the PI3K/AKT/mammalian target of rapamycin signaling pathway,upregulating the reactive oxygen species and activating stress response proteins.For chronic leukemia,PTL inhibits the NF-κB by alkylating cysteine residues and inhibits the leukemia cells by affecting glutathione system inducing reactive oxygen species.PTL can also increase the sensitivity of leukemia cells to chemotherapy-related drugs.The solubility and bioavailability of PTL can be improved by preparing poly(styrene maleic anhydride)-b-poly(styrene)micelles,poly(lactic-co-glycolic acid)and anti-CD44 encapsulation technology.Conclusion PTL has a good therapeutic effect on leukemia,but it needs to be modified and synthesized to become an ideal anti-leukemia drug.This study can provide ideas for the research and development of safe and efficient new leukemia drugs,as well as experimental basis and theoretical support for leukemia treatment.
万方数据
维普
